DK0831911T3 - Kombinationsterapi til behandling af kongestivt hjertesvigt med spironolacton og angiotensin II-antagonist - Google Patents

Kombinationsterapi til behandling af kongestivt hjertesvigt med spironolacton og angiotensin II-antagonist

Info

Publication number
DK0831911T3
DK0831911T3 DK96919173T DK96919173T DK0831911T3 DK 0831911 T3 DK0831911 T3 DK 0831911T3 DK 96919173 T DK96919173 T DK 96919173T DK 96919173 T DK96919173 T DK 96919173T DK 0831911 T3 DK0831911 T3 DK 0831911T3
Authority
DK
Denmark
Prior art keywords
angiotensin
receptor antagonist
spironolactone
combination therapy
heart failure
Prior art date
Application number
DK96919173T
Other languages
Danish (da)
English (en)
Inventor
Todd E Maclaughlan
Joseph R Schuh
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of DK0831911T3 publication Critical patent/DK0831911T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DK96919173T 1995-06-07 1996-06-05 Kombinationsterapi til behandling af kongestivt hjertesvigt med spironolacton og angiotensin II-antagonist DK0831911T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48608995A 1995-06-07 1995-06-07
PCT/US1996/009342 WO1996040258A2 (en) 1995-06-07 1996-06-05 Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
DK0831911T3 true DK0831911T3 (da) 2002-07-22

Family

ID=23930539

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96919173T DK0831911T3 (da) 1995-06-07 1996-06-05 Kombinationsterapi til behandling af kongestivt hjertesvigt med spironolacton og angiotensin II-antagonist

Country Status (16)

Country Link
US (1) US20040102423A1 (ja)
EP (1) EP0831911B1 (ja)
JP (1) JPH11509838A (ja)
KR (1) KR19990022723A (ja)
CN (1) CN1192696A (ja)
AT (1) ATE216261T1 (ja)
AU (1) AU6158096A (ja)
BR (1) BR9608505A (ja)
CA (1) CA2224222A1 (ja)
CZ (1) CZ291268B6 (ja)
DE (1) DE69620756T2 (ja)
DK (1) DK0831911T3 (ja)
ES (1) ES2175098T3 (ja)
IL (1) IL122246A (ja)
PT (1) PT831911E (ja)
WO (1) WO1996040258A2 (ja)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
AU3408801A (en) * 2000-02-18 2001-08-27 Takeda Chemical Industries Ltd Tnf-alpha inhibitors
CA2469435A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
EP1608319A4 (en) 2003-04-03 2007-02-28 Univ California IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
AU2005295167B2 (en) * 2004-10-20 2012-05-10 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
JP2008520744A (ja) * 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
NZ571182A (en) 2006-04-04 2010-09-30 Univ California Pyrazolo[3,4-d]pyrimidines
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
NZ587051A (en) 2008-01-04 2012-12-21 Intellikine Llc Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8637542B2 (en) * 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
ES2570429T3 (es) 2008-10-16 2016-05-18 Univ California Inhibidores de heteroaril quinasa de anillo condensado
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
ES2433225T3 (es) 2009-01-30 2013-12-10 Takeda Pharmaceutical Company Limited Compuesto con anillos condensados y uso del mismo
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103648499B (zh) 2011-01-10 2017-02-15 无限药品股份有限公司 用于制备异喹啉酮的方法及异喹啉酮的固体形式
CA2821985C (en) 2011-01-11 2019-07-09 Dimerix Bioscience Pty Ltd Combination therapy
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
CN102816126A (zh) * 2011-06-07 2012-12-12 中国药科大学 具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2925944C (en) 2013-10-04 2023-01-10 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016141182A1 (en) 2015-03-03 2016-09-09 Yee Richard W Compositions and methods for treating ocular diseases
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN109715615A (zh) 2016-06-29 2019-05-03 蒙特利尔大学 联芳甲基杂环
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3506100A1 (de) * 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CA2075627A1 (en) * 1990-02-13 1991-08-14 William J. Greenlee Angiotensin ii antagonists incorporating a substituted benzyl element
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
WO1992020662A1 (en) * 1991-05-10 1992-11-26 Merck & Co., Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
WO1994009778A1 (en) * 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases

Also Published As

Publication number Publication date
JPH11509838A (ja) 1999-08-31
EP0831911B1 (en) 2002-04-17
BR9608505A (pt) 1999-07-06
DE69620756T2 (de) 2002-11-14
DE69620756D1 (de) 2002-05-23
CZ291268B6 (cs) 2003-01-15
ATE216261T1 (de) 2002-05-15
CZ384897A3 (cs) 1998-05-13
WO1996040258A2 (en) 1996-12-19
EP0831911A2 (en) 1998-04-01
AU6158096A (en) 1996-12-30
US20040102423A1 (en) 2004-05-27
IL122246A (en) 2004-06-01
CA2224222A1 (en) 1996-12-19
IL122246A0 (en) 1998-04-05
CN1192696A (zh) 1998-09-09
KR19990022723A (ko) 1999-03-25
PT831911E (pt) 2002-09-30
ES2175098T3 (es) 2002-11-16
WO1996040258A3 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
DK0831911T3 (da) Kombinationsterapi til behandling af kongestivt hjertesvigt med spironolacton og angiotensin II-antagonist
WO1996040255A3 (en) Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
NZ310730A (en) Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure
DE69007740D1 (de) Substituierte 5-[(Tetrazolyl)alkenyl]-Imidazole.
NZ330889A (en) Cycloalkyl substituted imidazoles and their use in treating CSB/RK/p38 kinase mediated diseases
WO2004082599A3 (en) Combination of an aldosterone receptor antagonist and an anti-diabetic agent
MY110205A (en) Imidazolyl-alkenoic acids.
IE902139L (en) Imidazolyl alkenoic acids
EP0437103A3 (en) Substituted 5-(alkyl)carboxamide imidazoles
NO872863D0 (no) Analogifremgangsmaate for fremstilling av terapeutiske imidazoler som blokkerer angiotensin-ii-reseptorer.
WO2002009760A3 (en) Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
AU641952B2 (en) Substituted N-(imidazolyl)alkyl alanine derivatives
MXPA05010507A (es) Combinacion de un antagonista del receptor de aldosterona y un agente antiobesidad.
AU8534291A (en) Renal-selective angiotensin ii antagonists for treatment of hypertension
WO1992020651A3 (en) N-(heteroaryl)-imidazolyl-alkenoic acids
MX9709976A (es) Terapia de combinacion con espironolactona y antagonista de angiotensina ii para el tratamiento de fallas cardiacas congestivas.
MY118704A (en) Process for preparation of eprosartan
MX9709978A (es) Terapia de combinacion de antagonista de aldosterona epoxi-esteroidal y antagonista de angiotensina ii para tratamiento de insuficiencia cardiaca congestiva.
HU9402429D0 (en) Pyrazolopyrimidin derivatives as angiotensin ii receptor antagonists